Deerfield Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $47.3M | Hold |
145,000
| – | – | 0.86% | 28 |
|
|
2025
Q1 | $39.2M | Sell |
145,000
-191
| -0.1% | -$51.6K | 0.77% | 29 |
|
|
2024
Q4 | $34.2M | Buy |
145,191
+191
| +0.1% | +$44.9K | 0.65% | 37 |
|
|
2024
Q3 | $39.9M | Buy |
145,000
+25,200
| +21% | +$6.93M | 0.6% | 36 |
|
|
2024
Q2 | $29.1M | Buy |
+119,800
| New | +$29.1M | 0.48% | 43 |
|
|
2024
Q1 | – | Sell |
-1,574
| Closed | -$301K | – | 371 |
|
|
2023
Q4 | $301K | Buy |
+1,574
| New | +$301K | 0.01% | 121 |
|
|
2018
Q3 | – | Sell |
-146,000
| Closed | -$14.4M | – | 103 |
|
|
2018
Q2 | $14.4M | Hold |
146,000
| – | – | 0.51% | 69 |
|
|
2018
Q1 | $17.4M | Buy |
+146,000
| New | +$17.4M | 0.6% | 59 |
|
|
2016
Q3 | – | Sell |
-336,000
| Closed | -$18.6M | – | 92 |
|
|
2016
Q2 | $18.6M | Buy |
+336,000
| New | +$18.6M | 0.73% | 46 |
|
|
2014
Q3 | – | Sell |
-100,000
| Closed | -$6.32M | – | 122 |
|
|
2014
Q2 | $6.32M | Sell |
100,000
-202,000
| -67% | -$12.8M | 0.25% | 75 |
|
|
2014
Q1 | $20.3M | Buy |
+302,000
| New | +$20.3M | 0.83% | 37 |
|
|
2013
Q4 | – | Sell |
-383,158
| Closed | -$24.5M | – | 101 |
|
|
2013
Q3 | $24.5M | Sell |
383,158
-310,842
| -45% | -$19.9M | 1.14% | 37 |
|
|
2013
Q2 | $21.5M | Buy |
+694,000
| New | +$21.5M | 1.01% | 37 |
|